In a report released today, Suraj Kalia from Northland Securities maintained a Buy rating on BioLife Solutions (BLFS), with a price target of $18. The company’s shares opened today at $18.
“We continue to believe BioLife is one of the better small-cap plays with a lower risk exposure to the biotech / regen med space. Maintain OP rating. Key Points Overall revs = $5.5M, up 74% y/y.”
According to TipRanks.com, Kalia is a 5-star analyst with an average return of 12.9% and a 60.3% success rate. Kalia covers the Healthcare sector, focusing on stocks such as Tactile Systems Technology, Obalon Therapeutics Inc, and Apollo Endosurgery Inc.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for BioLife Solutions with a $21 average price target, which is a 16.7% upside from current levels. In a report released today, Maxim Group also maintained a Buy rating on the stock with a $24 price target.
See today’s analyst top recommended stocks >>
BioLife Solutions’ market cap is currently $322.6M and has a P/E ratio of 457.11. The company has a Price to Book ratio of 7.34.
Based on the recent corporate insider activity of 42 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of BLFS in relation to earlier this year. Most recently, in December 2018, Raymond Cohen, a Director at BLFS bought 5,357 shares for a total of $6,750.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
BioLife Solutions, Inc. engages in the development, manufacture, and marketing of portfolio of biopreservation tools for cells, tissues, and organs including proprietary clinical grade cell and tissue hypothermic storage and cryopreservation freeze media. Its products include CryoStor, BloodStor, HypoThermosol FRS, and Cell Thawing Media.